Abstract
This commentary reflects upon the study of Braga et al of open-label continuation electroconvulsive therapy (ECT) plus clozapine in treatment-resistant schizophrenia (TRS), as reported in this issue of The Journal of ECT. The evidence base for ECT in TRS is scant, and the study of Braga et al is a step forward. However, their report raises other important questions including (1) what is the proper frequency of continuation ECT in TRS, and (2) should TRS patients, even TRS patients who have failed clozapine, receive acute ECT + clozapine, or is ECT + conventional antipsychotics sufficient? In this commentary, we examine these questions and outline a future research strategy for TRS that includes large simple trials.
Original language | English (US) |
---|---|
Pages (from-to) | 153-155 |
Number of pages | 3 |
Journal | Journal of ECT |
Volume | 35 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2019 |
Externally published | Yes |
Keywords
- Antipsychotic Agents
- Clozapine
- Combined Modality Therapy
- Electroconvulsive Therapy
- Humans
- Pilot Projects
- Schizophrenia